Efficacy and safety of 8-week combination therapy for chronic hepatitis C with protease inhibitor narlaprevir
Gusev, D.A., Klimova, E.А., Znoyko, O.O., Isakov, V.A., Kropochev, V.S., Zhdanov, K.V., Kizhlo, S.N., Kozlov, K.V., Sukachev, V.S., Batskikh, S.N., Tarkhova, E.P., Krasavina, E.N., Samsonov, M.Yu, Yushchuk, N.D.
Published in Infectious diseases: News, Opinions, Training (2020)
Published in Infectious diseases: News, Opinions, Training (2020)
Get full text
Journal Article
Narlaprevir, ritonavir, and sofosbuvir in non-cirrhotic chronic hepatitis C genotype 1 infected patients
Klimova, E.А., Znoyko, O.O., Chulanov, V.P., Gusev, D.A., Isakov, V.A., Zhdanov, K.V., Batskikh, S.N., Kizhlo, S.N., Mamonova, N.A., Kozlov, K.V., Sukachev, V.S., Tarkhova, E.P., Krasavina, E.А., Samsonov, M.Yu, Yushchuk, N.D.
Published in Infectious diseases: News, Opinions, Training (2020)
Published in Infectious diseases: News, Opinions, Training (2020)
Get full text
Journal Article